Venetoclax penetrates in cerebrospinal fluid of an acute myeloid leukemia patient with leptomeningeal involvement

被引：0

作者：

Annalisa Condorelli

Cristina Matteo

Salvatore Leotta

Giovanni Schininà

Roberta Sciortino

Gianna Maria Piccolo

Nunziatina Laura Parrinello

Maria Proietto

Maria Grazia Camuglia

Massimo Zucchetti

Giuseppe Milone

Francesco Di Raimondo

机构：

[1] UOC di Ematologia Con Trapianto di Midollo Osseo AOU Policlinico G. Rodolico-San Marco,UOC di Anestesia

[2] Policlinico G. Rodolico-San Marco,Division of Neurology

[3] Azienda Ospedaliera Policlinico G.Rodolico-San Marco,Department of Oncology

[4] Istituto Di Ricerche Farmacologiche Mario Negri IRCCS,undefined

来源：

Cancer Chemotherapy and Pharmacology | 2022年 / 89卷

关键词：

Venetoclax; Acute myeloid leukemia; Leptomeningeal involvement; Relapse; Bone marrow transplantation;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Relapse at the central nervous system (CNS) in acute myeloid leukemia (AML) carries a dismal prognosis. Treatment options are limited to intrathecal therapy, high-dose cytarabine, high-dose methotrexate, and radiotherapy. Novel strategies are needed. Venetoclax has recently been approved by the FDA, in combination with hypomethylating agents or low-dose cytarabine, for elderly adults or patients ineligible for intensive chemotherapy affected by AML. However, little is known on its efficacy in patients with leptomeningeal involvement. Here, we present a case of a 52-year-old patient affected by AML relapsed at CNS after allogeneic bone marrow transplantation who was treated with venetoclax. We evaluated the concentration of the drug in cerebrospinal fluid (CSF) by HPLC MS/MS method on three different occasions to verify the penetration of the drug through the brain–blood barrier and we observed that the concentration in CSF was similar to the IC50 established in vitro.

引用

页码：267 / 270

页数：3

共 48 条

[1]

Pan R(2014)Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia Cancer Discov 4 362-375

[2]

Hogdal LJ(2016)Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia N Engl J Med 374 311-322

[3]

Benito JM(2016)Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia Cancer Discov 6 1106-1117

[4]

Bucci D(2018)Venetoclax with low-dose cytarabine induces rapid, deep, and durable responses in previously untreated older adults with AML ineligible for intensive chemotherapy Blood 132 284-284

[5]

Roberts AW(2018)Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study Lancet Oncol 19 216-228

[6]

Davids MS(2018)Response to venetoclax and hypomethylating agents among prognostic risk groups and genetic subtypes of acute myeloid leukemia Blood 132 334-334

[7]

Pagel JM(2018)Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia Haematologica 103 e404-e407

[8]

Konopleva M(2018)Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies Am J Hematol 93 401-407

[9]

Pollyea DA(2019)Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement Haematologica 104 e222-e223

[10]

Potluri J(2017)Evaluation of the pharmacokinetic interaction between venetoclax, a selective BCL-2 inhibitor, and warfarin in healthy volunteers Clin Drug Investig 37 303-309

← 1 2 3 4 5 →